domatinostat in combination with avelumab

DRUG2 trials

Sponsors

4SC AG

Conditions

Merkel Cell Carcinoma

Phase 2

Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1

CompletedNCT04393753

4SC AGMerkel Cell Carcinoma

Start: 2020-10-13End: 2024-02-26Updated: 2024-05-08

Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma (MERKLIN 1)

WithdrawnNCT04874831

4SC AGMerkel Cell Carcinoma

Start: 2021-11-01End: 2025-09-30Updated: 2021-11-18

Related Papers

A phase II, open-label study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with advanced unresectable/metastatic Merkel cell carcinoma progressing on anti-PD-(L)1 antibody therapy: The MERKLIN 2 study.

Journal of Clinical Oncology2021-05-202 citations